Ephedra Safety Risk Evidence Sufficient For Market Ban – Rep. Waxman
This article was originally published in The Tan Sheet
Executive Summary
There is currently enough evidence of risk to remove ephedra from the market, Rep. Henry Waxman (D-Calif.) maintained at the Food & Drug Law Institute's Annual Educational Conference in Washington, D.C. April 1
You may also be interested in...
Supplement Risk Limits Set “Substantially” Below Drugs By DSHEA, FDA Told
In the context of the Dietary Supplement Health & Education Act, the type of risk from dietary supplements that should be considered "significant or unreasonable" may be "substantially less serious than the types of risk that would be considered significant or unreasonable for drugs," according to April 4 congressional comments to FDA
Supplement Risk Limits Set “Substantially” Below Drugs By DSHEA, FDA Told
In the context of the Dietary Supplement Health & Education Act, the type of risk from dietary supplements that should be considered "significant or unreasonable" may be "substantially less serious than the types of risk that would be considered significant or unreasonable for drugs," according to April 4 congressional comments to FDA
Supplement Risk Limits Set “Substantially” Below Drugs By DSHEA, FDA Told
In the context of the Dietary Supplement Health & Education Act, the type of risk from dietary supplements that should be considered "significant or unreasonable" may be "substantially less serious than the types of risk that would be considered significant or unreasonable for drugs," according to April 4 congressional comments to FDA